Share on StockTwits

Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Bryan E. Roberts sold 823,350 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $12.71, for a total transaction of $10,464,778.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

IRWD has been the subject of a number of recent research reports. Analysts at BMO Capital Markets upgraded shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Friday. Separately, analysts at Jefferies Group cut their price target on shares of Ironwood Pharmaceuticals from $12.00 to $11.00 in a research note to investors on Thursday, October 24th. They now have a “hold” rating on the stock. Finally, analysts at Zacks reiterated an “outperform” rating on shares of Ironwood Pharmaceuticals in a research note to investors on Thursday, October 24th. They now have a $12.00 price target on the stock. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the stock. Ironwood Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $13.49.

Ironwood Pharmaceuticals (NASDAQ:IRWD) traded down 4.17% during mid-day trading on Monday, hitting $12.40. 1,300,197 shares of the company’s stock traded hands. Ironwood Pharmaceuticals has a 1-year low of $8.95 and a 1-year high of $19.67. The stock’s 50-day moving average is $11.48 and its 200-day moving average is $11.23. The company’s market cap is $1.498 billion.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Tuesday, October 22nd. The company reported ($0.51) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.57) by $0.06. The company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $6.54 million. During the same quarter last year, the company posted $0.42 earnings per share. Ironwood Pharmaceuticals’s revenue was down 94.9% compared to the same quarter last year. On average, analysts predict that Ironwood Pharmaceuticals will post $-2.42 earnings per share for the current fiscal year.

Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.